Fundamental Considerations for Genetically-Guided Pain Management with Opioids Based on CYP2D6 and OPRM1 Polymorphisms.
Gualberto Ruano, Jonathan A Kost
https://pubmed.ncbi.nlm.nih.gov/30508992/Actively Recruiting
Led by Research Inc · Updated on 2026-09-09
200
Participants Needed
1
Research Sites
13 weeks
Total Duration
Researchers are studying how genetic differences in the CYP2D6 enzyme affect pain relief and side effects in patients who have surgery and receive tramadol through an elastomeric infusion pump. This observational study compares patients with non-normal CYP2D6 metabolizer types to those with normal metabolizers to see how these differences impact analgesic treatment failure and adverse effects after surgery. All participants receive the same standard tramadol pump as part of routine postoperative care. Before or shortly after surgery, a blood or buccal sample is taken to determine CYP2D6 genotype, but this information does not guide treatment during the 72-hour observation period. The study analyzes outcomes separately for poorintermediate and rapidultrarapid metabolizer groups while considering other factors like organ function and additional medications. Participants are monitored for 72 hours after surgery for pain levels, need for rescue medication, pump discontinuation, sedation, breathing status, nausea, vomiting, and other side effects. Data on analgesic failure and adverse effects are collected at set times. The main outcome is the incidence of analgesic treatment failure within one week, with adverse effects and phenotype-specific outcomes also assessed. The study aims to improve understanding of how genetics influences tramadol effectiveness and safety in postoperative pain management.
CONDITIONS
Prospective Pharmacogenetic Cohort Study of CYP2D6 Metabolizer Phenotype, Analgesic Failure, and Adverse Effects in Postoperative Patients Receiving Tramadol by Elastomeric Infusion Pump
E
Edison Osorio, MD, Plastic surgeon
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Research Inc
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 72 hours
Participants receive standard postoperative care with a tramadol elastomeric analgesia pump. Pain levels and side effects are monitored closely for 72 hours without changes to treatment based on genetic results.
Assessments at prespecified times during 72 hours
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Gualberto Ruano, Jonathan A Kost
https://pubmed.ncbi.nlm.nih.gov/30508992/Zalina Zahari, Rusli Ismail
https://pubmed.ncbi.nlm.nih.gov/23759977/Mahmood Mahajna, Rami Abu Fanne, Mahmoud Odeh...
https://pubmed.ncbi.nlm.nih.gov/38440181/Larisa H Cavallari, Rachel A Myers, Hrishikesh Chakraborty...
https://pubmed.ncbi.nlm.nih.gov/41719044/Soizic Percevault, Blandine De La Gastine, Laurent Varin...
https://pubmed.ncbi.nlm.nih.gov/41791456/Siew Hua Gan, Rusli Ismail, Wan Aasim Wan Adnan...
https://pubmed.ncbi.nlm.nih.gov/17570739/Research Inc
Lead Sponsor